Premium
Diabetes‐induced Changes in Mannan‐binding Lectin Levels and Complement Activation in a Mouse Model of Type 1 Diabetes
Author(s) -
Østergaard J. A.,
Bjerre M.,
DagnæsHansen F.,
Hansen T. K.,
Thiel S.,
Flyvbjerg A.
Publication year - 2013
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/sji.12027
Subject(s) - mannan binding lectin , diabetes mellitus , complement system , medicine , lectin pathway , endocrinology , type 1 diabetes , type 2 diabetes , lectin , diabetic nephropathy , immunology , biology , alternative complement pathway , immune system
Circulating mannan‐binding lectin ( MBL ) levels are elevated in type 1 diabetes. Further, high MBL levels are associated with the development of diabetic nephropathy. In animals, a direct effect of MBL on diabetic kidney changes is observed. We hypothesized that MBL levels and detrimental complement activation increase as a consequence of diabetes. We measured plasma MBL before and 7 weeks after inducing diabetes by streptozotocin. Mice have two MBL s, MBL ‐A and MBL ‐C. Diabetes induction led to an increase in MBL ‐C concentration, whereas no change during the study was found in the control group. The increase in MBL ‐C was associated with the increasing plasma glucose levels. In accordance with the observed changes in circulating MBL levels, liver expression of Mbl2 m RNA (encoding MBL ‐C) was increased in diabetes. Mbl1 expression (encoding MBL ‐A) did not differ between diabetic and control animals. The estimated half‐life of recombinant human MBL was significantly prolonged in mice with diabetes compared with control mice. Complement activation in plasma and glomeruli did not differ between groups. We demonstrate for the first time that MBL levels increase after induction of diabetes and in parallel with increasing plasma glucose. Our findings support the previous clinical observations of increased MBL in type 1 diabetes. This change may be explained by alternations in both MBL production and turnover.